Hair
Alopecia Areata
search
Alopecia Areata
, Alopecia Totalis, Alopecia Universalis, Exclamation Point Hair
See Also
Alopecia
Definitions
Alopecia Areata
Non-scarring autoimmune
Alopecia
Epidemiology
No gender predominance
Most common under age 30 years
Children account for 20% of patients
Prevalence
: 0.2% up to 2% of U.S. population
Pathophysiology
Autoimmune reaction to
Hair Follicle
s
Prematurely transitions
Anagen
phase (growth) hairs to
Catagen
or
Telogen
phase (with more rapid loss)
Often associated with
Thyroid
disease
Types
Patch
y Alopecia Areata
Well circumscribed, flesh colored, smooth, discrete oval patches of
Hair Loss
Ophiasis
Band-like
Hair Loss
around temporal and occipital scalp
Alopecia Totalis
Hair Loss
over entire scalp
Alopecia Universalis
Hair Loss
over entire body
Signs
Characteristics
Well-demarcated oval or round patches of
Hair Loss
Patch
es of
Hair Loss
may coalesce into larger areas of
Hair Loss
Distribution
Hair Loss
on scalp is most common (but may occur in any body region)
Timing
Hair Loss
develops over the course of weeks
Exclamation Point Hairs at edges of
Hair Loss
(as visualized under microscope)
Club shaped
Hair Root
Thin proximal
Hair Shaft
Normal caliber distal
Hair Shaft
Non-specific findings
Short
Vellus Hair
s or 2-3 mm broken hairs
Black or yellow dots on scalp
Positive
Hair Pull Test
Associated nail findings
Nail Pitting
(most common)
Other nail findings
Trachyonychia
Beau Lines
Onychorrhexis
Onychomadesis
Nail thickness changes (thinning or thickening)
Leukonychia
(transverse or punctate)
Koilonychia
Lunula red marks
Labs
Options Based on Presentation
KOH Scraping of patch
Thyroid Stimulating Hormone
(TSH)
Rapid Plasma Reagin
(RPR)
Erythrocyte Sedimentation Rate
(ESR)
Complete Blood Count
(CBC)
Antinuclear Antibody
(ANA)
Rheumatoid Factor
(RF)
Differential Diagnosis
Other non-scarring
Alopecia
Tinea Capitis
Associated Conditions
Atopic Dermatitis
Diabetes Mellitus
Rheumatoid Arthritis
Vitiligo
Thyroid
disease
Pernicious Anemia
Discoid Lupus Erythematosus
Management
Moderate Involvement (<50% of scalp involved)
Intralesional
Triamcinolone
(
Kenalog
)
Treatment of choice
Dilute
Kenalog
40 mg/ml with saline to 10 mg/ml
Kenalog
40 mg/ml: 0.5 ml
Saline: 2 ml
Inject 0.1 ml into patch at 1 cm intervals
Inject into mid-
Dermis
via 0.5 inch 30 gauge needle
Adverse effects: Atrophy
Avoid injecting too superficially
Avoid injecting >0.1 ml or >10 mg/ml per site (3 ml total per session)
Limit injections to no more often than every 4-6 weeks
Continue until resolution or to a maximum of 6 months
Adjuncts to intralesional injection
Apply
Topical Minoxidil
5% solution twice daily or
Apply mid-potency
Topical Corticosteroid
(eg.
Kenalog
0.1%)
Apply 1 ml to entire scalp twice daily
Consider in children with Alopecia Areata
Management
Severe Involvement (>50% of scalp involved)
Consider wig or hairpiece
Gene
ral: Combination therapy often used
Contact sensitizers with intralesional
Kenalog
Most effective option
Usually requires referral to dermatology
Minoxidil
5% bid with
Topical Steroid
s or
Anthralin
Topical
Anthralin
Cream (Psoriatec) 0.5 to 1% cream
Course usually limited to 6 months
Apply daily and leave on for 5 minutes to start
Gradually increase time applied up to 60 minutes
Rinse scalp well and then clean with soap
New
Hair Growth
seen within 3 months
Mid-potency
Topical Corticosteroid
(eg.
Kenalog
0.1%)
Apply 1 ml to entire scalp twice daily
Topical Minoxidil
5%
Use as adjunct to
Anthralin
or
Corticosteroid
Prednisone
(less commonly used)
Start: 40 mg orally daily for 7 days
Taper: Decrease by 5 mg q3 days
Course completed within 6 weeks
Dermatology
Consultation
Contact sensitizer
Dinitrochlorobenzene
Diphen
ylcyclopropenone
Squaric acid dibutyl ester
Disease Modifying Antirheumatic Drug
Methotrexate
Immunosuppressant
s (e.g.
Azathioprine
)
Course
Spontaneously resolves in 6-12 months in most limited presentations (<50% scalp involved)
Hair
pigmentation may be different in regrowth area
Some cases progress (see prognostic indicators below)
Recurs in 30% of cases (often affects same area)
Prognosis
Indicators of poor prognosis
Course duration longer than one year
Onset of
Alopecia
prior to
Puberty
Family History
of Alopecia Areata
Atopic Patient
s
Down Syndrome
References
Bertolino (2000) Postgrad Med 107(7): 81-90 [PubMed]
Darwin (2018) J Trichology (2):51-60 [PubMed]
Longfellow (2022) Am Fam Physician 105(3): 317-8 [PubMed]
Madani (2000) J Am Acad Dermatol 42: 549-66 [PubMed]
Phillips (2017) Am Fam Physician 96(6): 371-8 [PubMed]
Springer (2003) Am Fam Physician 68(1):93-102 [PubMed]
Thiedke (2003) Am Fam Physician 67(5):1007-18 [PubMed]
Type your search phrase here